Downregulation of Wip-1 phosphatase expression in MCF-7 breast cancer cells enhances doxorubicin-induced apoptosis through p53-mediated transcriptional activation of Bax

Cancer Biology and Therapy

Volumn 8, Issue 6, 2009, Pages 555-563

  Kong, Weihong ^a,b   Jiang, Xiaoshan ^a   Mercer, W Edward ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b Jefferson Alumni Hall ^*  (United States)

Author keywords

Apoptosis; Bax; Doxorubicin; MCF7; p53; Wip1 PPM1D

Indexed keywords

ACTIN; COMPLEMENTARY RNA; CYCLIN DEPENDENT KINASE INHIBITOR 1; DOXORUBICIN; LUCIFERASE; MESSENGER RNA; PHOSPHATASE; PROTEIN BAX; PROTEIN P53; PROTEIN WIP 1; SERINE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; APOPTOSIS; ARTICLE; BAX GENE; BREAST CANCER; CANCER CELL CULTURE; CELL CLONE; CELL STRAIN MCF 7; CONTROLLED STUDY; DNA DAMAGE; DOWN REGULATION; GENE AMPLIFICATION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; ONCOGENE; P53 GENE; PLASMID; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REPORTER GENE; TRANSCRIPTION INITIATION; WILD TYPE; WIP 1 GENE;

ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; BASE SEQUENCE; BCL-2-ASSOCIATED X PROTEIN; BREAST NEOPLASMS; CELL LINE, TUMOR; DOXORUBICIN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENES, REPORTER; HUMANS; PHOSPHOPROTEIN PHOSPHATASES; PHOSPHORYLATION; PROMOTER REGIONS, GENETIC; RNA INTERFERENCE; TRANSCRIPTIONAL ACTIVATION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 66149098135     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.8.6.7742     Document Type: Article

References (38)

1. Wahl GM, Carr AM. The evolution of diverse biological responses to DNA damage: insights from yeast to p53. Nature Cell Biol 2001; 3:228-277
2. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer 2002; 2:594-604. (Pubitemid 37328926)
3. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408:307-309
4. Appella E, Anderson CW. Post-translational modifications and activation of p53 by genotoxic stresses. Eur J Biochem 2001; 268:2764-2772 (Pubitemid 32862957)
5. Fiscella M, Zhang H, Fan S, Sakaguchi K, Shen S, Mercer WE, et al. Wip-1, a novel human protein phosphatase that is induced in response to ionizing radiation in a p53-dependent manner. Proc Natl Acad Sci USA 1997; 94:6048-6053 (Pubitemid 27270633)
6. Kallioniemi A, Kallioniemi OP, Piper J, Tanner M, Stokke T, Chen L, et al. Detection and mapping of amplified DNA sequences in breast cancer by comparative genomic hybridation. Proc Natl Acad Sci USA 1994; 91:2156-2160 (Pubitemid 24092062)
7. Li J, Yang Y, Peng Y, Austin RJ, van Eyndhoven WG, Nguyen KCQ, et al. Oncogenic properties of PPM1 D located within a breast cancer amplification epicenter at 17q23. Nat Genet 2001; 31:133-134
8. Ried T, Petersen I, Holtgreve-Grez H, Speicher MR, Schrock E, du Manoir S. Mapping of multiple DNA gains and losses in primary small cell line carcinomas by comparative genomic hybridization. Cancer Res 1994; 54:1801-1806
9. Solinas-Todo S, Wallrapp G, Muller-Pillasch F, Bentz M, Gress T, Lichter P. Mapping of chromosomal imbalances in pancreatic carcinoma by comparative genomic hybridization. Cancer Res 1996; 56:3803-3807 (Pubitemid 26272032)
10. VoorterC, Joos S, Bringuier PP, Vallinga M, Poddighe P, Schalken J, du Manoir S, Ramaekers F, Lichter P and Hopman A. Detection of chromosomal imbalances in transitional cell carcinomas of the bladder by comparative genomic hybridization. Am J Pathol 1995; 146:1341-1354
11. Hirasawa A, Saito-Ohara F, Inoue J, Aoki D, Susums N, Yokoyama T, Norawa S, Inazawa J and Imoto I. Association of 17q21-q24 gain in ovarian clear cell adenocarcinomas with poor prognosis and identification of PPM 1 D and APPBP2 as likely amplification targets. Clin Cancer Res 2003; 9:1995-2004. (Pubitemid 36687618)
12. Plantaz D, Mohapatra G, Matthay KK, Pellarin M, Seeger R and Feuerstein BG. Gain of chromosome 17 is the most frequent abnormality detected in neuroblastoma by comparative genomic hybridization. Am J Pathol 1997; 150:81-89 (Pubitemid 27027099)
13. Takekawa M, Adachi M, Nakahata A, Nakayama I, Itoh F, Tsukuda H, Taya Y and Imai K. p53-inducible Wip-1 phosphatase mediates a negative feedback regulation of p38 MAPK-p53 signaling in response to UV radiation. EMBO J 2000; 19:6517-6526
14. Shreeram S, Demidov ON, Hee WK, Yamaguchi H, Onishs N, Kek C, Trimofeev ON, Dudgeon C, Fornace AJ, Anderson CW, Minami Y, Appella E and Bulavin DV. Wip-1 phosphatase modulates ATM-dependent signaling pathways. Molecular Cell 2006; 23:757-764 (Pubitemid 44308587)
15. Lu J, Yang Y, Peng Y, Austin RJ, van Eyndhoven WG, Nguyen KCQ, Gabriele T, McCurrach ME, Marks JR, Hoey T, et al. PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints. Genes & Dev 2005; 19:1162-1174
16. Fujimoto H, Onishi N, Kato N, Takekawa M, Xu XZ, Kosugi A, Kondo T, Oishi I, Yoda A, Imamura M and Minami Y. Regulation of anti-oncogenic Chk2 kinase by the oncogenic Wip-1 phosphatase. Cell Death and Differ 2005; 13:1-11.
17. Sinclair CS. Rowley M, Naderi A and Couch FJ. The 17q23 amplicon and breast cancer. Breast Cancer Research and Treatment 2003; 78:313-322 (Pubitemid 36543211)
18. Rauta J, Alarmo EL, Kauraniemi P, Karhu R, Kuukasjarvi T and Kallioniemi A. The serinethreonine protein phosphatase PPM1 D is frequently activated through amplification in aggressive primary breast tumors. Breast Cancer Research and Treatment 2006; 95:257-263
19. Oda K, Arakawa H, Tanaka T, Matauda K, Tanikawa C, Mori T, Tokino T, Nakamura K, Tokino T, Nakamura Y and Taya Y. p53AIP-1, a potential mediator of p53-dependent apoptosis and its regulation by Ser-46 phosphorylated p53. Cell 2000; 20:849-862
20. Fiscella M, Ullrich SJ, Zambrano N, Shields MT, Lin D, Lees-Miller SP, Anderson CW, Mercer WE and Appella E. Mutation of the serine15 phosphorylation site of human p53 reduces the ability of p53 to inhibit cell cycle progression. Oncogene 1993; 8:1519-1528 (Pubitemid 23189048)
21. Lambert PF, Kashanchi F, Radonovich MF, Shiekhattar R and Brady JN. Phosphorylation of p53 serine 15 increases interaction with CBP, J BioI Chem 1998; 273:33048-33053 (Pubitemid 28557701)
22. Saito S, Yamaguchi H, Higashimoto Y, Choa C, Xu Y, Fornace AJ, Appella E and Anderson CW. Phosphorylation site interdependence of human p53 post-translational modifications in response to stress. J BioI Chem 2003; 278:37536-37544 (Pubitemid 37175275)
23. Bulavin DV, Saito S, Hollander CM, Sakaguchi K, Anderson CW, Appella E and Fornace AJ. Phosphorylation of human p53 by p38 kinase corrdinates N-terminal phosphorylation and apoptosis in response to UV radiation. EMBO Journal 1999; 18:6845-6854
24. Sakakura C, Sweeney EA, Shirahama T, Igarashi Y, Sen-itiroh H, Nakatani H, et al. Overexpression of bax sensitizes human breast cancer MCF-7 cells to radiation induced apoptosis. 1nl Journal of Cancer 1998; 67:101-105
25. Saito-Ohara F, Imoto I, Inoue J, Hosoi H, Nakagaware A, Sugimoto T and Inszawa J. PPM1D is a potential target for 17q gain in neuroblastoma. Cancer Res 2003; 63:1876-1883 (Pubitemid 36460852)
26. Cho J, Nannenga B, Demidov ON, Bulavin DV, Cooney A, Brayton C, Zhang Y, Mbawuike IN, Bradely A, Appella E and Donehower LA. Mice deficient for the wild type p53-induced phosphatase gene (Wip-1) exhibit defects in reproductive organs, immune function and cell cycle control. Mol Cell Biol 2002; 22:1094-1105 (Pubitemid 34094846)
27. Bulavin DV, Demido ON, Saito S, Kauran P, Phillips C, Amundson SA, Ambrosino C, Sauter G, Nebreda AR, Anderson CW, Kallioniemi A, Fornace AJ and Appella E. Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity Nat. Genetics 2002; 31:210-215
28. Weinstein IB. Cancer: Addiction to oncogenes-the Achilles heal of cancer. Science 2002; 297:63-64 (Pubitemid 34743088)
29. Sharma SV, Fischbach MA, Haber DA and Settleman J. "Oncogenic Shock": Explaining oncogene addition through differential signal attenuation. Clin Cancer Res 2006; 12:4392-4395
30. Masuda K, Shima H, Katagiri G and Kituchi K. Activation of ERK induces phosphorylation of MAPK phosphatase-7 a JNK specific phosphatase at ser446. J Biol Chem 2003; 278:32448-32456 (Pubitemid 37048443)
31. Tanoue T, Yamamoto T, Maeda R and Hishida E. A novel phosphatase MKP-7 acts preferentially on JUN/SAPK and p38 α and β MAPKs J. Bioi Chem 2001; 267:26629-26639 (Pubitemid 37412886)
32. Xia Z, Dickens M, Raingeaud J, Davis RJ and Greenberg ME. Opposing effects of ERK and JUN-p38 MAP kinases on apoptosis. Science 1995; 270:1326-1331
33. Thornborrow EC and Manfredi JJ. One mechanism for cell type specific regulation of the Bax promoter by the tumor suppressor p53 is dictated by the p53 responsive element. J Biol Chem 1999; 274:33747-33756 (Pubitemid 129511691)
34. El-Diery WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW and Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75:817-825 (Pubitemid 23346378)
35. Szak ST, Mays D and Pietenpol JA. Kinetics of p53 binding to promoters in vivo. Mol Cell Biol 2001; 21:3375-3386 (Pubitemid 32381773)
36. Kaeser MD and Iggo RD. Chromatin immunoprecipitation analysis fails to support the latency model for regulation of p53 DNA binding activity in vivo. Proc Natl Acad Sci 2002; 99:95-100. (Pubitemid 34060322)
37. Samuels-Iev Y, O'Connor DJ, Bergamacchi D, Trigiante G, Hsieh J-K, Zhong S, Campargue I, Naumovski L, Crook T and Lu X. ASPP proteins specifically stimulate the apoptotic function of p53. Mol Cell 2004; 8:781-794
38. Reinhardt HC, Asian AS, Lees JA and Yaffe MB. p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. Cancer Cell 2007; 11:175-189 (Pubitemid 46209849)